• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Quest Diagnostics Declares Quarterly Cash Dividend

    5/14/25 6:17:00 PM ET
    $DGX
    Medical Specialities
    Health Care
    Get the next $DGX alert in real time by email

    SECAUCUS, N.J., May 14, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on July 21, 2025 to shareholders of record of Quest Diagnostics common stock on July 7, 2025.

    Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)

    About Quest Diagnostics

    Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our more than 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-declares-quarterly-cash-dividend-302455896.html

    SOURCE Quest Diagnostics

    Get the next $DGX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DGX

    DatePrice TargetRatingAnalyst
    4/2/2025$195.00Buy
    Redburn Atlantic
    3/4/2025$185.00Buy → Neutral
    Citigroup
    1/6/2025$169.00 → $174.00Market Perform → Outperform
    Leerink Partners
    12/17/2024$145.00 → $172.00Equal-Weight → Overweight
    Morgan Stanley
    12/10/2024$175.00 → $185.00Buy
    Jefferies
    10/23/2024$157.00 → $182.00Neutral → Outperform
    Robert W. Baird
    8/28/2024$165.00In-line
    Evercore ISI
    7/10/2024$145.00 → $165.00Neutral → Buy
    Citigroup
    More analyst ratings

    $DGX
    Leadership Updates

    Live Leadership Updates

    See more
    • Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health

      Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, N.J., Jan. 17, 2024 /PRNewswire/ -- Fitbit and Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced a collaboration to study the potential of wearable devices to improve metabolic health, which influences risk of developing several diseases, including diabetes and heart disease. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair beh

      1/17/24 8:58:00 AM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics Board of Directors Elects James E. Davis Chairman of the Board

      SECAUCUS, N.J., March 3, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors elected James E. Davis, the company's Chief Executive Officer and President, to serve in the additional position of Chairman of the Board of Directors, effective April 1, 2023. "The Board carefully considered our governance structure and determined that combining the roles of Chairman and CEO under Jim Davis's leadership is in the best interest of shareholders to successfully continue to execute

      3/3/23 4:30:00 PM ET
      $DGX
      Medical Specialities
      Health Care
    • Quotient Limited Announces Appointment of Chief Financial Officer

      JERSEY, Channel Islands, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Ali Kiboro as the Company's Chief Financial Officer (CFO). Mr. Kiboro will assume the responsibilities of CFO on November 1st, 2021, replacing Mr. Peter Buhler who will support the Company during the transitional phase, as needed, before leaving Quotient Limited at year-end. "I am delighted to welcome Ali to the Executive team at this exciting time in our Company's evolution. He brings over 20 years of experience in global finance and has been a key driver of operational excellence in a career spanning healthcare services and manufacturing. I w

      10/12/21 8:45:00 AM ET
      $DGX
      $QTNT
      Medical Specialities
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $DGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

      SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

      2/13/24 5:12:21 PM ET
      $DGX
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

      SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

      1/25/24 12:16:40 PM ET
      $DGX
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

      SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

      2/7/23 1:25:52 PM ET
      $DGX
      Medical Specialities
      Health Care

    $DGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Redburn Atlantic initiated coverage on Quest Diagnostics with a new price target

      Redburn Atlantic initiated coverage of Quest Diagnostics with a rating of Buy and set a new price target of $195.00

      4/2/25 8:51:11 AM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics downgraded by Citigroup with a new price target

      Citigroup downgraded Quest Diagnostics from Buy to Neutral and set a new price target of $185.00

      3/4/25 7:20:57 AM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Quest Diagnostics from Market Perform to Outperform and set a new price target of $174.00 from $169.00 previously

      1/6/25 7:49:06 AM ET
      $DGX
      Medical Specialities
      Health Care

    $DGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP & Chief Commercial Officer Delaney Mark E sold $306,800 worth of shares (1,748 units at $175.51), decreasing direct ownership by 19% to 7,498 units (SEC Form 4)

      4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

      5/14/25 5:12:30 PM ET
      $DGX
      Medical Specialities
      Health Care
    • Executive Vice President & CFO Samad Sam increased direct ownership by 0.28% to 26,451 units (SEC Form 4)

      4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

      5/2/25 4:33:33 PM ET
      $DGX
      Medical Specialities
      Health Care
    • SVP, Clinical Solutions Kuppusamy Karthik increased direct ownership by 0.26% to 10,612 units (SEC Form 4)

      4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

      5/2/25 4:32:51 PM ET
      $DGX
      Medical Specialities
      Health Care

    $DGX
    Financials

    Live finance-specific insights

    See more
    • Quest Diagnostics Declares Quarterly Cash Dividend

      SECAUCUS, N.J., May 14, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on July 21, 2025 to shareholders of record of Quest Diagnostics common stock on July 7, 2025. About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take acti

      5/14/25 6:17:00 PM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics Reports First Quarter 2025 Financial Results; Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025

      First quarter revenues of $2.65 billion, up 12.1% from 2024First quarter reported diluted earnings per share ("EPS") of $1.94, up 12.8% from 2024; and adjusted diluted EPS of $2.21, up 8.3% from 2024Full year 2025 reported diluted EPS now expected to be between $8.62 and $8.87; and adjusted diluted EPS is expected to remain between $9.55 and $9.80SECAUCUS, N.J., April 22, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2025. "In the fir

      4/22/25 6:43:00 AM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics to Release First Quarter 2025 Financial Results on April 22, 2025

      SECAUCUS, N.J., April 1, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2025 financial results on Tuesday, April 22, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on www.Q

      4/1/25 4:23:00 PM ET
      $DGX
      Medical Specialities
      Health Care

    $DGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Quest Diagnostics Declares Quarterly Cash Dividend

      SECAUCUS, N.J., May 14, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on July 21, 2025 to shareholders of record of Quest Diagnostics common stock on July 7, 2025. About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take acti

      5/14/25 6:17:00 PM ET
      $DGX
      Medical Specialities
      Health Care
    • Oncologists Report Seeing More Advanced Cancers and Say Current Tests Are Not Catching Cancer Recurrence Early Enough, New Quest Diagnostics Report Finds

      More than 3 in 4 oncologists (76%) feel they are seeing more advanced cancers, and of these, 75% believe that screening barriers are the leading cause, although nearly one-third (32%) cite "factors that we don't understand yet"Missed/delayed follow-up care or monitoring appointments by patients (68%) and imaging tests not detecting recurrence early enough (50%) are among the primary reasons cancer recurrence is typically missed, according to oncologists whose patients' cancer recurrence was missed in an earlier stage94% of oncologists say circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing could reduce diagnosis delays in cancer recurrence but cite hurdles to wide adoptionSE

      5/13/25 6:03:00 AM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics Reports First Quarter 2025 Financial Results; Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025

      First quarter revenues of $2.65 billion, up 12.1% from 2024First quarter reported diluted earnings per share ("EPS") of $1.94, up 12.8% from 2024; and adjusted diluted EPS of $2.21, up 8.3% from 2024Full year 2025 reported diluted EPS now expected to be between $8.62 and $8.87; and adjusted diluted EPS is expected to remain between $9.55 and $9.80SECAUCUS, N.J., April 22, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2025. "In the fir

      4/22/25 6:43:00 AM ET
      $DGX
      Medical Specialities
      Health Care

    $DGX
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Quest Diagnostics Incorporated

      SCHEDULE 13G - QUEST DIAGNOSTICS INC (0001022079) (Subject)

      5/14/25 10:45:25 AM ET
      $DGX
      Medical Specialities
      Health Care
    • SEC Form 144 filed by Quest Diagnostics Incorporated

      144 - QUEST DIAGNOSTICS INC (0001022079) (Subject)

      5/13/25 9:59:16 AM ET
      $DGX
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Quest Diagnostics Incorporated

      10-Q - QUEST DIAGNOSTICS INC (0001022079) (Filer)

      4/23/25 4:21:36 PM ET
      $DGX
      Medical Specialities
      Health Care